Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries

AIDS Patient Care and STDs

Volumn 16, Issue 12, 2002, Pages 599-608

  Wagner, Glenn J ^a  

^a RAND CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AGED; ARTICLE; COGNITIVE DEFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONITORING; PATIENT COMPLIANCE; PREVALENCE; SELF REPORT; SYMPTOMATOLOGY; VIRUS LOAD;

EID: 0036908649     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729102761882134     Document Type: Article

References (45)

1. U.S. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Washington, D.C., 2001.
2. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
3. Bangsberg DR, Hecht FM, Charlebois E, Chesney M, Moss AR. Comparing objective methods of adherence assessment: Electronic medication monitoring and unannounced pill count. AIDS Behav 2001;5:275-281.
4. Arnsten JH, Demas PA, Farzadegan H, et al. Anti-retroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clin Infect Dis 2001;33: 1417-1423.
5. Matthews WC, Mar-Tang M, Ballard C, et al. Predictors, prevalence, and therapeutic effect of early adherence after starting or changing antiretroviral therapy. AIDS Patient Care STDs 2002;16:255-270.
6. Bangsberg DR, Hecht FM, Clague H, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr 2001;26:435-442.
7. Kasrissios H, Suárez JR, Katzenstein D, Girard P, Sheiner LB, Blaschke TF. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS 1998;12:2295-2303.
8. Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials 2001;2:38-45.
9. Arnsten J, Demas P, Gourevitch M, Buono D, Farzadegan H, Schoenbaum E. Adherence and viral load in HIV-infected drug users: Comparison of self-report and medication event monitors (MEMS) [abstract 69]. VII Conference on Retroviruses and Opportunistic Infections, 2000.
10. Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy. Soc Sci Med 2000;50:1599-1605.
11. Schulz RM. Depression scores and antiretroviral therapy adherence in HIV disease [abstract I-215]. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, California, September 24-27, 1998.
12. Shelton D, Marconi K, Pounds MB, Scopetta M. Medical adherence among prenatal, HIV seropositive African American women: Family issues. Family Systems Med 1993;11:343-356.
13. Brown M, Inouye J, Powell-Cope GM, et al. Social support and adherence in HIV+ persons. XII International AIDS Conference, Abstract 32346. Geneva, Switzerland, June 28-July 3, 1998.
14. Roberts KJ. Barriers to and facilitators of HIV-positive patients' adherence to antiretroviral treatment regimens, AIDS Patient Care STDS 2000;14:155-168.
15. Wenger N, Gifford A, Liu H, et al. Patient characteristics and attitudes associated with antiretroviral adherence. VI Conference on Antiretrovirals and Opportunistic Infections. Chicago, Illinois, January 31 February 4, 1999.
16. Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 1999;37:213-255.
17. Tuldra A, Fumaz CR, Ferrer MJ, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve longterm adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;25:221-228.
18. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAiliffe TL. Patterns, correlates and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol 2000;19:124-133.
19. Gifford AG, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000;23:386-395.
20. Eldred L, Wu A, Chaisson RE, Moore RD. Adherence to antiretroviral therapy in HIV disease. IV Conference on Retrovirus and Opportunistic Infections. Washington, D.C., 1997.
21. Gifford AL, Shively MJ, Bormann JE, Timberlake D, Bozzette SA. Self-reported adherence to combination antiretroviral medication regimens in a community-based sample of HIV-infected adults [abstract 32338]. XII International AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
22. Johnston BE, Ahmad K, Smith C, Rose DN. Adherence to highly active antiretroviral therapy among HIV-infected patients of the inner city [abstract 32389]. XII International AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
23. Ohmit S, et al. Adherence to antiretroviral therapy among women in the HIV Epidemiology Research Study (HERS) and Women's Inter-Agency HIV Study (WIHS) [Abstract 32347]. XII International AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
24. Bartlett JA. Correlation between antiretroviral pill burden and durability of virologic response - A systematic overview. XIII International AIDS Conference, Abstract and poster presentation ThPeB4998. Durban, South Africa, July 9-14, 2000.
25. Farthing C. Steps towards improving adherence. The ART of HIV Management, Satellite Symposium. XIII International AIDS Conference. Durban, South Africa, July 9-14, 2000.
26. Luber AD, et al. Patient adherence with twice daily dosing of nelfinavir equivalent to non-nucleoside reverse transcriptase inhibitors (NNRTI) when given in combination with dual nucleoside analogues (NRTI). XIII International AIDS Conference, Abstract and poster presentation ThPeB4991. Durban, South Africa, July 9-14, 2000.
27. Becker S, Rachlis A, Gill J, et al. Successful substitution of protease inhibitors with efavirez (EFV) in patients with undetectable viral loads - A prospective, randomized, multicenter, open-label study (DMP-049). VIII Conference on Retroviruses and Opportunistic Infections, Abstract 20. Chicago, Illinois, February 4-8, 2001.
28. Mehta S, Moore RD, Graham NM. Potential factors affecting adherence with HIV therapy. AIDS 1997;11: 1665-1670.
29. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. AIDS Care 2000;12:255-266.
30. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001;134:968-977.
31. Straka RJ, Fish JT, Benson SR, Suh JT. Patient self-reporting of compliance does not correspond with electronic monitoring: An evaluation using isosoride dinitrate as a model drug. Pharmacotherapy 1997;17:126-132.
32. Wagner GJ, Ghosh-Dastidar B. Electronic monitoring: Adherence assessment or intervention? HIV Clin Trials 2002;3:45-51.
33. Stall R, Hoff C, Coates T, et al. Decisions to get HIV tested and to accept antiretroviral therapies among gay/bisexual men: Implications for secondary prevention efforts. J Acquir Immune Defic Syndr Hum Retrovir 1996;11:151-160.
34. Delis DC, Kramer JH, Kaplah E, et al. California Verbal Learning Test, Research Edition. Cleveland, OH: Psychological Corporation, 1983.
35. Army Individual Test Battery, Manual of Directions and Scoring. Washington, D.C.: War Department, 1944.
36. Wechsler D. Wechsler Adult Intelligence Scale-Revised. New York: Psychological Corporation, 1981.
37. Heaton RK, Grant I, Matthews CG. Comprehensive Norms for an Expanded Halstead-Reitan Battery. Odessa, FL: Psychological Assessment Resources. 1992.
38. Norman MA, Evans JD, Miller SW, Heaton RK. Demographically corrected norms for the California Verbal Learning Test. J Clin Exp Neuropsychol 2000;22: 80-94.
39. Spitzer RL, Williams JBW, Gibbon M. Structured Clinical Interview for DSM-IV. Washington, D.C.: American Psychiatric Press, 1995.
40. Beck A, Beamsesderfer A. Assessment of depression: The depression inventory. In: Pichot P, ed. Psychological Measurements in Psychopharmacology. Basel: S. Karger, 1974;151-169.
41. DiIorio C, Faherty B, Manteuffel B. Epilepsy self-management: Partial replication and extension. Res Nurs Health 1994;7:167-174.
42. Morse EV, Simon PM, Coburn M, Hyslop N, Greenspan D, Balson PM. Determinants of subject compliance within an experimental anti-HIV drug protocol. Soc Sci Med 1991;10:1161-1167.
43. Coyne JC, Ellard JH, Smith DAF. Social support, interdependence and the dilemmas of helping. In: Sarason IG, Sarason BR, Pierce GR, eds. Social Support: An Interactional View. New York: Wiley, 1990, pp. 129-149.
44. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001;28:445-449.
45. Nieuwkerk PT, Sprangers MA, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001;161:1962-1968.